PARP inhibitor–associated folate deficiency anemia
Following PARPi initiation for BRCA1/2 -related malignancies, at least 3.1% of patients developed marked folate deficiency anemia, precipitating hemoglobin decreases from 11.1 (IQR 9.9-12.1) to 7.0 g/dL (IQR 6.3-7.4) ( P < 0.001), PRBC transfusion dependence (62.5%), and cancer treatment disruptions (75%).
Authors
- D.I. Nathan
- Noa Rippel (ORCID: https://orcid.org/0000-0002-0083-6321)
- Ilan Shapira
- P. Klein
- J. M. Liu
- W. Fu
Institutions
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Blood Red Cells & Iron
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1016/j.brci.2026.100052
- Primary Topic
- Folate and B Vitamins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00